New Blood Test May Protect MS Patients from PML Risk

Credibility

Interest

Key Takeaway

A new blood test can help identify MS patients at risk for a serious brain infection called PML.

What They Found

Researchers discovered that a special blood test called the IFN-γ release assay can detect certain immune cells related to a virus called JC virus (JCV). This virus can cause a serious condition known as Progressive Multifocal Leukoencephalopathy (PML) in people with weakened immune systems. They found that 84% of patients with active PML tested positive using this blood test. In people with Multiple Sclerosis (MS) on a specific treatment called natalizumab for a long time, about 36% showed a positive result, indicating a higher risk for PML. This means the test could be a useful tool to find out who might be more likely to develop PML.

Who Should Care and Why

MS patients, especially those on long-term treatment with natalizumab, should care about these findings because it can help doctors identify who is at risk for PML. Just like a smoke detector alerts you to a fire risk, this blood test could alert patients and doctors to a potential health threat. Caregivers also benefit because they can be more aware of signs of PML and seek help sooner if needed. Knowing the risk can lead to better monitoring and possibly changing treatment plans to prevent serious complications. Overall, this test could help improve safety and health outcomes for MS patients.

Important Considerations

This study focused on a specific group of patients, so results might not apply to everyone with MS. The blood test's accuracy is high, but it doesn't mean everyone who tests positive will get PML. More research is needed to confirm how best to use this test in everyday patient care.

Categories:

Early Research MS Genetics Living with MS

Article Topics:

AIDSIFN-γ release assayJC viruseffector T cellseffector memory T cellsmultiple sclerosisnatalizumabprogressive multifocal leukoencephalopathy

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Frontiers in immunology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News